ProfileGDS5678 / 1423750_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 91% 90% 92% 90% 90% 90% 90% 88% 90% 90% 91% 89% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0630889
GSM967853U87-EV human glioblastoma xenograft - Control 27.4572791
GSM967854U87-EV human glioblastoma xenograft - Control 37.2034390
GSM967855U87-EV human glioblastoma xenograft - Control 47.7643492
GSM967856U87-EV human glioblastoma xenograft - Control 57.225290
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0500890
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0506490
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1853790
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8398288
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2013890
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2325290
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4425891
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0743889
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1531890